Compare Deutsche Bank AG (DB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Vertex Pharmaceuticals Incorporated — how do they compare? Deutsche Bank AG trades at $33.72 (market cap $62.42B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2× Deutsche Bank AG's market cap, and Deutsche Bank AG pays a 3.46% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DB | VRTX | |
|---|---|---|
Market Cap | $62.42B | $127.55B |
Volume | 2,918,760 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $41.56 | $557.96 |
52-Week Low | $28.37 | $407.37 |
Typical Hold Time | 80 Days | 120 Days |
Enterprise Value | $77.06B | $121.68B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% on concerns about Q3 investment banking revenue. The stock shows attractive valuation metrics with P/E of 9.09 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B and profit margin expanding to 21.59%. Technical indicators signal bearish momentum with the price near key support at $33. Recent news highlights the bank's strategic focus on wealth management growth and 2028 return targets.
The outlook remains balanced - strong fundamentals and undervaluation provide upside potential, but near-term headwinds in investment banking and technical weakness suggest cautious optimism. Key risks include execution on strategic targets and market-sensitive revenue streams, while analyst consensus leans neutral with 58% hold ratings.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
